Hetero launches generic version of Covid-19 drug Favipiravir

Our Bureau Hyderabad | Updated on July 29, 2020 Published on July 29, 2020

Hetero’s Favivir is priced at ₹59 per tablet   -  REUTERS

Generic and antiretroviral drug maker, Hetero, has launched generic Favipiravir in India under the brand name ‘Favivir.’

Hetero has been granted the manufacturing and marketing approval for Favipiravir from the Drug Controller General of India (DCGI).

Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of Covid-19. It is an oral antiviral medication that has demonstrated positive clinical outcomes. Favivir improves treatment accessibility to a significant amount of Covid patient population, which usually sustains mild to moderate symptoms.

Hetero’s Favivir is priced at ₹59 per tablet and is marketed and distributed by Hetero Healthcare Limited. The product is available at all retail medical outlets and hospital pharmacies across the country and will be sold only on prescription.

Backed by vertical integration capabilities, the drug is being manufactured at the formulation facility in India, which has been approved by stringent global regulatory authorities such as USFDA and the EU, among others, the Hyderabad-based company said in a release.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 29, 2020
This article is closed for comments.
Please Email the Editor